NCT00534885 - Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Hepatitis A

Interventions

BIOLOGICAL

Healive® Lot 1

Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

BIOLOGICAL

Healive® Lot 2

Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

BIOLOGICAL

Healive® Lot 3

Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

BIOLOGICAL

Havrix

Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart

Trial Locations (1)

Changzhou City Center for Disease Control and Prevention, Changzhou

All Listed Sponsors

lead

Sinovac Biotech Co., Ltd

INDUSTRY